Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

Garry Dolton(Cardiff University), Cristina Rius(Cardiff University), Aaron Wall(Cardiff University), Barbara Szomolay, Valentina Bianchi(Cardiff University), Sarah A. E. Galloway(Cardiff University), Md Samiul Hasan(Cardiff University), Théo Morin(Cardiff University), Marine E. Caillaud(Cardiff University), Hannah Thomas(Cardiff University), Sarah M. Theaker(Cardiff University), Li Rong Tan(Cardiff University), Anna Fuller(Cardiff University), Katie Topley(Cardiff University), Mateusz Legut(Cardiff University), Meriem Attaf(Cardiff University), Jade R. Hopkins(Cardiff University), Enas M. Behiry(Cardiff University), Joanna Zabkiewicz(Cardiff University), Caroline Alvares(Cardiff University), Angharad Lloyd(Cardiff University), Amber Rogers(Cardiff University), Peter Henley(Cardiff University), Chris Fegan(Cardiff University), Oliver G. Ottmann(Cardiff University), Stephen Man(Cardiff University), Michael D. Crowther(University Hospital of Wales), Marco Donia(Copenhagen University Hospital), Inge Marie Svane(Copenhagen University Hospital), David K. Cole(Cardiff University), Paul E. Brown(University of Warwick), P.J. Rizkallah(Cardiff University), Andrew K. Sewell(Cardiff University)
Cited by 127Open Access
Full Text

Abstract

The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a proteomic database to reveal the antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could target multiple different tumor types via the HLA A∗02:01-restricted epitopes EAAGIGILTV, LLLGIGILVL, and NLSALGIFST from Melan A, BST2, and IMP2, respectively. Atomic structures of a TCR bound to all three antigens revealed the importance of the shared x-x-x-A/G-I/L-G-I-x-x-x recognition motif. Multi-epitope targeting allows individual T cells to attack cancer in several ways simultaneously. Such “multipronged” T cells exhibited superior recognition of cancer cells compared with conventional T cell recognition of individual epitopes, making them attractive candidates for the development of future immunotherapies.


Related Papers

No related papers found

Powered by citation graph analysis